ORLANDO, Fla.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI) today announced that updated data from the ZEVALIN (ibritumomab tiuxetan) injection for intravenous use Phase 3 First-line Indolent Trial (FIT) released in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting by independent researchers demonstrated that after a median follow-up of 66.2 months, patients with previously untreated follicular non-Hodgkin’s lymphoma treated with a standard, single-dose infusion of ZEVALIN as part of the ZEVALIN Therapeutic Regimen after partial or complete response to first-line chemotherapy had a nearly three-year advantage in median progression-free survival (PFS) compared to patients treated with either chemotherapy alone or chemotherapy plus rituximab (49 months versus 14 months).
